CEL-SCI Corporation heads into its May 13 earnings print with one of the most aggressive short-selling buildups in the small-cap biotech space right now.
The lending market tells the sharpest story. Cost to borrow has exploded from under 5% just two weeks ago to 343% annually — a move of nearly 6,000% in a single week. That is not a gradual repositioning. Short sellers rushed into CVM after April 30, driving estimated short interest from roughly 845,000 shares to 3.66 million in just seven trading sessions — a 336% weekly increase. Short interest now represents nearly 46% of the free float. Availability in the lending pool has tightened dramatically alongside that borrow cost surge, and the ORTEX short score has hit 99.8 out of 100, placing CVM in the most-shorted tier of the entire universe. The stock has already paid a heavy price: it has fallen 65% over the past month and dropped another 17% in Monday's session alone, closing at $1.41.
The bear case is written in the lending data. A biotech with no apparent analyst coverage and an enterprise value in the low $30 millions is being shorted at a rate that implies conviction about further downside — whether from a clinical readout, a cash position concern, or dilution risk. CEO Geert Kersten did buy $200,000 worth of shares in January at $5.26, a signal of internal confidence that now looks painfully underwater. That purchase represented the most significant insider activity in the trailing 90 days, with net insider buying of roughly $250,000 over that period. At today's price of $1.41, the gap between that buy price and the current level underscores the severity of the collapse.
The only available analyst price target — $25.00, dated to early March — is so far removed from the current price that it carries no practical weight in this context and likely predates the recent collapse entirely. Options data is also stale by nearly a year and cannot be used to characterise current sentiment. What can be said is that the stock has reacted violently to recent events: over the last four earnings or announcement events, one-day moves ranged from -8% to +11%, and five-day moves swung between -16% and +27%. The asymmetry in those reactions suggests CVM is the kind of name where the binary outcome dominates everything else.
The May 13 print will test whether the catalyst that triggered this short surge — whatever its nature — is confirmed or contradicted by the company's own numbers and forward commentary.
See the live data behind this article on ORTEX.
Open CVM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
